Navigation Links
Yongye Biotechnology Announces Record Third Quarter Results
Date:11/13/2008

trative

Expenses 453,683 196,386 1,265,808 351,372

Income from

Operations 5,030,277 1,247,634 14,788,294 4,802,412

Other Income

(Expense)

Interest Income 65,785 -- 66,563 1,291

Other Income (340,087) (81,827) (726,927) (279,468)

Total Other Income

(Expenses) (274,302) (81,827) (660,364) (278,177)

Income (Loss)

Before Provision

for Income Taxes

and Minority

Interest 4,755,975 1,165,807 14,127,930 4,524,235

Provision for

Income Taxes 227,537 -- 822,302 --

Net Income (Loss)

before Minority

Interest 4,528,438 1,165,807 13,305,628 4,524,235

Provision for

Minority Interest 57,421 -- 1,092,426 --

Net Income 4,471,017 1,165,807 12,213,202 4,524,235

Foreign Currency

Translation

Adjustment 5,199 170,033 419,970 344,228

Comprehensive

Income $4,476,216 $1,335,840 $12,633,172 $4,868,463

Net Income Per

Share

Basic $0.24 $0.10 $0.78 $0.40

Diluted $0.22 $0.10 $0.75 $0.40

Weighted Average

Shares

Basic 18,637,948 11,444,775 15,654,417 11,444,775

Diluted 20,103,760 11,444,775 16,335,237 11,444,775

YONGYE BIOTECHNOLOGY INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

Yongye Biotechnology The predecessor

International, Inc. Inner Mongolia


'/>"/>

SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
2. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
3. Yongye Biotechnology International Raises $9.4 Million in Private Placement
4. Yongye Biotechnology International Announces Second Quarter Results
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Retains CCG Investor Relations
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
9. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
10. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
(Date:5/21/2013)... new study led by George Washington University Professor ... of ice in small droplets is strongly size-dependent, ... the nanoscale. The formation of ice at the ... whose answer also has important implications for climate ... of ice from supercooled water is generally initiated ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Smarter Security, ... security solutions, today announced that Genzyme, a Sanofi company ... of Door Detective® CL for a multi-use facility in ... in four other Genzyme buildings, this latest order underscores ... the tailgate detection device improving doorway access ...
(Date:5/21/2013)... ROCKVILLE, Md. , May 21, 2013 /PRNewswire/ ... "Phase 1 study of margetuximab (MGAH22), an Fc-modified ... solid tumors expressing the HER2 oncoprotein," will be ... American Society of Clinical Oncology during the Developmental ... June 3 at 4:15 – 4:30 PM.  The ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... by Improving ... Information Management, MILFORD, ... announced that it has joined the BioIT Alliance, an,initiative spearheaded ... and software companies,working together to realize the potential of personalized ...
... StopAfib.org, at, http://www.StopAfib.org, announces that September is Atrial ... called afib or AF., Once considered benign, this ... or stroke. Every five minutes, someone in the,U.S. has ... killer and the #1 cause of,permanent disability, and takes ...
... $15 million development milestone payment to InterMune - ... - Roche to lead ITMN-191 program in Phase 2 -, ... ) today announced that InterMune has earned a $15 million,development ... virus (HCV) NS3 protease inhibitor compound ITMN-191,(referred to as R7227 ...
Cached Biology Technology:Waters Brings Advanced Laboratory Data Management to Microsoft's BioIT Alliance 2Waters Brings Advanced Laboratory Data Management to Microsoft's BioIT Alliance 3Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4
(Date:5/22/2013)... engineers must join together in a major new effort ... crisis in providing Earth,s people with clean water that ... of a comment article in the current edition of ... of the American Chemical Society (ACS), the world,s largest ... Sedlak, Ph.D., and Jerald L. Schnoor, Ph.D., explain that ...
(Date:5/22/2013)... can endanger the whole organism, as they may lead ... in Munich now report how byproducts of respiration cause ... DNA in our cells controls the form and function ... for this are encoded in the linear sequence of ... (A), cytosine (C), guanine (G) and thymine (T). Random ...
(Date:5/22/2013)... pollinating insects and wild plants have slowed in recent ... by the University of Leeds and the Naturalis Biodiversity ... reductions in the diversity of species in Britain, Belgium ... But the picture brightened markedly after 1990, with a ... hoverflies and wild plants. , Professor Bill ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... CORVALLIS, Ore. A 700-mile security wall under construction ... alter the movement and "connectivity" of wildlife, biologists say, ... populations of some species. However, technology and alterations ... animals to move more freely between the two countries, ...
... survival is now better understood. For the first time, ... National Laboratory observed the chemical changes in individual cells ... them. The team tracked the chemical changes in ... can only exist in an oxygen-free environment. They exposed ...
... has discovered a key process in cell growth that can ... assistant professor of biochemistry, found that an overabundance of the ... well as a shortage of the p53 molecule, will lead ... Plk1 molecule indirectly attacks p53 in a process called ubiquitination. ...
Cached Biology News:US-Mexico border wall could threaten wildlife species 2US-Mexico border wall could threaten wildlife species 3US-Mexico border wall could threaten wildlife species 4Scientists track chemical changes in cells as they endure extreme conditions 2Scientists track chemical changes in cells as they endure extreme conditions 3Protein can help cells or cause cancer, Purdue researcher finds 2
Request Info...
...
...
... Inhibits several important steps of angiogenesis including proliferation, ... Also reduces intracellular reactive oxygen species (ROS) level, ... cells. Formula: ... MolWeight: 360.31484 ...
Biology Products: